Malignant Peripheral Nerve Sheath Tumors

Slide 1 · Malignant peripheral nerve sheath tumors

Pathogenesis • morphology • diagnostic reasoning

Malignant transformation • neural origin • spindle-cell morphology

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Explain how NF1-associated and sporadic MPNSTs arise.

Link NF1, CDKN2A/B and PRC2 abnormalities to tumor biology.

Recognize the key architectural and cytologic features of MPNST.

Use clinicopathologic context to assess spindle-cell sarcomas.

Slide 3 · Where MPNST fits among nerve sheath tumors

Schwannoma

Benign, typically encapsulated; Arises adjacent to a nerve.

Neurofibroma

Benign, mixed cellular tumor that may expand nerve fascicles.

MPNST

Malignant lesion; Often infiltrates parent nerve and soft tissue.

Slide 4 · Common nerve-sheath lineage

Schwann-cell lineage

Schwannoma

Neurofibroma

MPNST

Schwannoma, neurofibroma and MPNST show evidence of Schwann-cell differentiation.

Slide 5 · MPNST is a malignant soft-tissue tumor

Most MPNSTs are high grade, but low-grade variants are recognized.

Its malignant phenotype includes destructive infiltration and, in many cases, marked cytologic atypia.

Diagnosis requires integration of morphology with neural and clinical context.

Slide 6 · Two principal clinical settings

NF1-associated

Approximately half of MPNSTs occur in people with NF1; Many are linked to preexisting plexiform neurofibroma.

Sporadic

MPNST can arise de novo without a known NF1 diagnosis.

Slide 7 · NF1 and sporadic occurrence are not equivalent

Among MPNST cases

~half

Are NF1-associated

Among people with NF1

~5–10%

Develop MPNST (Robbins)

“About half in NF1” describes the proportion of MPNST cases associated with the syndrome.

Slide 8 · NF1-associated malignant transformation

NF1 background

Inherited predisposition

Plexiform neurofibroma

Common benign precursor

Additional changes

Progression toward malignancy

MPNST

Infiltrative malignant tumor

Slide 9 · Sporadic MPNST: A distinct presentation

Some tumors develop de novo rather than through a clinically recognized neurofibroma.

Absence of a hereditary syndrome does not exclude MPNST.

Nerve continuity and tumor morphology remain important clues.

Slide 10 · Typical anatomic associations

Axial compartments

Chest, abdomen and pelvis.

Neck

Larger peripheral nerve trajectories.

Limb girdles

Proximal limb-associated nerves.

Slide 11 · Why location matters to pathology

Schematic: Tumor permeating nerve axis and adjacent tissue

Pale blue: Longitudinal nerve

Red outline: Infiltrative tumor

MPNSTs are frequently associated with large nerves, so anatomic relationships may be demonstrable.

Slide 12 · The clinical question is often a deep mass

A nerve-associated mass may be benign or malignant; Clinical history alone is not diagnostic.

NF1 status raises the pretest suspicion of MPNST in a deep soft-tissue lesion.

Histologic evidence of malignancy and a demonstrable nerve relationship carry substantial weight.

Slide 13 · Neurofibromatosis type 1: Relevant context

NF1 is an autosomal dominant systemic tumor-predisposition disorder.

Neurofibromas and MPNSTs are recognized neoplastic manifestations.

Expression is variable, and some patients have markedly severe disease.

Slide 14 · Neurofibromin restrains RAS signaling

Functional NF1

Neurofibromin present

RAS control

GTPase regulation limits RAS activity

Loss of NF1

RAS remains more active

Slide 15 · NF1 acts as a tumor-suppressor gene

The NF1 gene encodes neurofibromin, a negative regulator of RAS activity.

Neoplastic Schwann cells in NF1-related neurofibromas have biallelic NF1 defects.

Loss of the second functional copy is relevant to tumor development.

Slide 16 · Mosaicism and variable NF1 expression

NF1 has high penetrance but variable expressivity.

Mosaicism can produce disease localized to parts of the body.

A limited apparent phenotype does not negate an NF1-associated tumor.

Slide 17 · Neurofibroma is not a uniform entity

Cutaneous

Superficial, often pedunculated nodules.

Diffuse

Plaque-like infiltrating lesions of skin or soft tissue.

Plexiform

Expansion of multiple nerve fascicles; NF1-associated.

Slide 18 · Why the plexiform variant matters

Plexiform neurofibromas involve nerve roots or larger nerves.

The growth pattern expands several nerve fascicles rather than forming a single discrete mass.

This variant as the usual neurofibroma precursor of MPNST.

Slide 19 · Normal fascicles versus plexiform expansion

Schematic: Multiple fascicles enlarge while remaining recognizable

Green rings show separate expanded fascicular units

Plexiform neurofibroma expands multiple discrete fascicles.

Slide 20 · Plexiform neurofibroma: Gross appearance

Involved nerves become thickened, ropy and multinodular.

The classic “bag of worms” description reflects multiple expanded fascicles.

A plexiform pattern is a marker of syndrome association and precursor context, not proof of MPNST.

Slide 21 · Plexiform neurofibroma: Microscopic context

Bland spindle cells are admixed with stromal cell populations.

The matrix may be loose, myxoid or collagen-rich.

Collagen bundles may resemble “shredded carrots”; Entrapped axons are characteristic of the architecture.

Slide 22 · The neurofibroma microenvironment

NF1-deficient Schwann cell

Neoplastic compartment

KIT ligand

Signaling to mast cells

NF1-haploinsufficient mast cells

Enhanced stromal response

Growth-promoting factors

Support tumor-cell expansion

Slide 23 · Progression risk in NF1

The Robbins text reports MPNST in approximately 5%–10% of NF1 patients.

Numerous plexiform neurofibromas and large NF1 deletions are associated with higher risk.

These are patient-level associations, not histologic diagnostic criteria.

Slide 24 · Malignancy is not an inevitable outcome

Plexiform neurofibroma is a recognized precursor, but malignant transformation affects only a subset of NF1 patients.

Most benign nerve-sheath tumors do not become MPNST.

The key question is which lesions show malignant progression.

Slide 25 · Schwannoma is a contrasting benign pattern

Schwannomas generally form encapsulated, circumscribed masses.

They typically abut rather than infiltrate their parent nerve.

Antoni A/B areas and Verocay bodies support a schwannoma diagnosis.

Slide 26 · Benign–malignant growth-pattern contrast

Feature

Schwannoma

Plexiform neurofibroma

MPNST

Nerve relation

Abuts nerve

Expands fascicles

Infiltrates nerve axis

Boundary

Encapsulated

Fascicular nodularity

Poorly defined

Cells

Schwann-cell pattern

Mixed bland cells

Often atypical spindled cells

Biologic behavior

Benign

Benign precursor

Malignant

Slide 27 · Genetic complexity in MPNST

MPNSTs show complex chromosomal gains and losses.

The molecular profile goes beyond simple loss of neurofibromin.

Additional alterations accompany the development of high-grade disease.

Slide 28 · Conceptual sequence of progression

Loss of NF1 activity

RAS dysregulation

Additional tumor-suppressor defects

Cell-cycle control eroded

Chromatin repression defects

Transcriptional regulation altered

High-grade phenotype

Invasive, proliferative tumor

Slide 29 · CDKN2A/B: Growth-control locus

High-grade MPNST can show homozygous loss of CDKN2A/B.

The region encodes tumor-suppressive functions associated with cell-cycle and p53 regulation.

Deletion is an ancillary molecular clue in the appropriate setting.

Slide 30 · P16 links CDKN2A to cell-cycle control

CDKN2A

Genomic locus

P16

Cell-cycle brake

Proliferation

If restraint is lost

Loss removes restraint

P16 is a cell-cycle regulator encoded by CDKN2A.

Slide 31 · P14ARF connects to the p53 network

CDKN2A also encodes p14ARF, identified by Robbins as a p53 regulator.

Homozygous deletion may remove more than one tumor-suppressor function.

The specific pathway lesion must not be inferred from morphology alone.

Slide 32 · Polycomb repressive complex 2 (PRC2)

H3

H3

H3

H3

PRC2 activity

H3K27 methylation → transcriptional repression

PRC2 is a chromatin-modifying repressor complex.

Slide 33 · H3K27me3 is a repression-associated mark

H3K27me3 denotes trimethylation of histone H3 at lysine 27.

PRC2 contributes to deposition of this mark.

PRC2 impairment can therefore be reflected by reduced or absent H3K27me3 staining.

Slide 34 · PRC2 loss: Molecular event to tissue marker

PRC2 dysfunction

Chromatin regulator lost

Reduced H3K27me3

Repressive mark diminished

IHC readout

Tumor nuclear loss may be observed

Slide 35 · H3K27me3 loss is not universal

Published systematic evidence shows complete loss in a subset of high-grade MPNSTs.

Retained staining cannot by itself exclude MPNST.

The finding is supportive only within an integrated diagnostic assessment.

Slide 36 · H3K27me3 is not stand-alone proof

The mark can be diminished in other tumors by different mechanisms.

Patterns of staining and internal controls matter to interpretation.

A single IHC result does not replace clinicopathologic correlation.

Slide 37 · Separate the roles of three molecular clues

Alteration

Biologic role

Diagnostic interpretation

NF1 loss

Growth-signaling restraint lost

Supports syndrome-related pathway

CDKN2A/B loss

Cell-cycle regulator loss

Additional progression-associated change

PRC2 loss

Chromatin repression impaired

Can correlate with H3K27me3 loss

Slide 38 · Avoid a one-mutation diagnostic rule

MPNST commonly accumulates multiple genomic abnormalities.

Robbins treats molecular findings as clues alongside morphology and clinical evidence.

Neither NF1 history nor one molecular result is sufficient in isolation.

Slide 39 · Gross appearance: Infiltrating mass

MPNSTs are poorly circumscribed rather than neatly encapsulated.

Tumor spreads into the surrounding soft tissues.

The gross boundary may not correspond to an anatomic nerve compartment.

Slide 40 · Tumor extension along a nerve

Schematic: Tumor permeating nerve axis and adjacent tissue

Pale blue: Longitudinal nerve

Red outline: Infiltrative tumor

Growth commonly follows the longitudinal axis of the parent nerve.

Slide 41 · Invasion versus benign displacement

Displacement

Schwannoma usually remains separate from and adjacent to much of the nerve.

Expansion

Plexiform neurofibroma broadens multiple nerve fascicles.

Infiltration

MPNST permeates nerve axis and nearby soft tissue.

Slide 42 · Microscopic architecture: Spindle-cell fascicles

Typical MPNST is composed of elongated spindle cells.

Cells often aggregate into interlacing or sweeping fascicles.

Fascicular architecture is suggestive but not specific for MPNST.

Slide 43 · Why the tumor can look “marbleized”

Schematic: Alternating higher and lower cellular density

Low-power sections can alternate between relatively cellular and less cellular areas.

Slide 44 · The full morphologic spectrum is broad

Not every MPNST has the same density or arrangement of spindle cells.

Typical morphology provides a useful entry point; Less differentiated tumors are harder to classify.

Use the tumor as a whole rather than overcalling a small isolated field.

Slide 45 · Nuclear anaplasia is a key malignant feature

Marked cytologic atypia is often present in high-grade MPNST.

Anaplasia reflects a departure from the bland spindle-cell appearance of neurofibroma.

The finding is one part of the malignancy assessment.

Slide 46 · Mitoses indicate active proliferation

Mitotic activity is common in typical high-grade MPNST.

Mitoses should be interpreted alongside atypia and growth pattern.

Robbins provides no numerical cutoff in this section; Do not invent one.

Slide 47 · Necrosis supports high-grade behavior

Necrosis is another commonly encountered high-grade feature.

It is meaningful when coupled with cellular atypia and mitoses.

Necrosis is not disease-specific and must not be used alone to name MPNST.

Slide 48 · A composite high-grade pattern

Architecture

Infiltration, fascicular spindle cells, heterogeneous cellularity.

Cytology

Anaplasia and mitotic activity.

Tissue response

Necrosis and invasion of adjacent soft tissues.

Slide 49 · Low-grade MPNST: Necessary qualification

Although the majority of MPNSTs are high grade, lower-grade variants are recognized.

The absence of conspicuous necrosis or severe atypia does not settle every diagnostically challenging case.

No numeric grading algorithm is specified by the supplied Robbins passage.

Slide 50 · Reading a spindle-cell section systematically

Low power

Boundary, nerve relationship, cellularity pattern

Intermediate power

Fascicles and interface with tissue

High power

Atypia, mitoses, necrosis

Correlation

NF1, precursor lesion and molecular clues

Slide 51 · Divergent differentiation: Definition

MPNST may contain focal components with another recognizable line of differentiation.

Robbins terms the phenomenon “divergent differentiation”.

The additional component exists within an otherwise nerve-sheath malignancy.

Slide 52 · Recognized heterologous elements

Glandular

Epithelial-type gland structures.

Cartilaginous

Chondroid elements.

Osseous

Bone-forming elements.

Rhabdomyoblastic

Skeletal-muscle-type differentiation.

Slide 53 · Glandular differentiation

Focal gland-like structures are a described divergent component.

A glandular focus does not by itself displace the underlying MPNST diagnosis.

It demands careful exclusion of alternative biphasic tumor types.

Slide 54 · Cartilaginous and osseous differentiation

Cartilage or bone can be represented as heterologous tissue within MPNST.

These foci demonstrate lineage divergence, not a separate primary skeletal tumor.

Interpret the differentiated focus in relation to the dominant spindle-cell lesion.

Slide 55 · Triton tumor: Rhabdomyoblastic differentiation

An MPNST containing rhabdomyoblastic differentiation is called a Triton tumor.

The term is based on the divergent skeletal-muscle phenotype.

It should not be applied to all pleomorphic or spindle-cell MPNSTs.

Slide 56 · Divergent differentiation complicates classification

Heterologous foci can distract from the underlying nerve-sheath lineage.

The pathologist must identify the malignant background and its relationship to a nerve.

A single unusual area cannot substitute for assessment of the overall lesion.

Slide 57 · Why MPNST diagnosis can be difficult

Poorly differentiated MPNST may resemble undifferentiated spindle-cell sarcoma.

Typical histology is not pathognomonic.

Robbins explicitly recommends using context, anatomic continuity and molecular evidence.

Slide 58 · Four evidence domains support the diagnosis

Clinical

Documented NF1 diagnosis.

Anatomic

Tumor associated with a parent nerve.

Precursor

Transition from or association with neurofibroma.

Molecular

Changes supporting the MPNST pathway.

Slide 59 · NF1 history changes interpretation

A spindle-cell malignancy in a patient with NF1 deserves careful evaluation for MPNST.

The syndrome is supportive but not definitive evidence.

An unrelated soft-tissue tumor remains possible in an NF1 patient.

Slide 60 · Demonstrating neural continuity

Schematic: Tumor permeating nerve axis and adjacent tissue

Pale blue: Longitudinal nerve

Red outline: Infiltrative tumor

Identify whether a named nerve enters or courses through the lesion.

Slide 61 · A preexisting neurofibroma is a second clue

Many NF1-associated MPNSTs are thought to arise in plexiform neurofibromas.

Residual neurofibroma can establish the precursor context.

Absence of visible precursor tissue does not rule out a de novo tumor.

Slide 62 · Comparing a neurofibroma with MPNST

Domain

Neurofibroma

MPNST

Tumor cells

Bland; Mixed stromal elements

Often atypical spindle cells

Growth pattern

Fascicular expansion / infiltration by benign cells

Destructive nerve-axis and soft-tissue invasion

Mitoses / necrosis

Not defining findings

Common in high-grade tumors

Association

NF1 especially plexiform type

NF1-related or sporadic

Slide 63 · Comparing schwannoma with MPNST

Domain

Schwannoma

MPNST

Tumor boundary

Well circumscribed, encapsulated

Poorly defined

Nerve interaction

Abuts; Typically noninvasive

Infiltrates along nerve

Architecture

Antoni A / Antoni B; Verocay bodies

Fascicular, variably cellular

Biologic behavior

Benign

Predominantly high-grade malignant

Slide 64 · The spindle-cell sarcoma differential

High-grade spindle-cell morphology overlaps multiple soft-tissue malignancies.

A compatible fascicular pattern is not by itself a lineage assignment.

When neural differentiation is uncertain, report and investigate the unresolved differential.

Slide 65 · How to interpret ancillary test findings

Genetic or epigenetic findings may increase confidence in a suspected MPNST.

H3K27me3 immunostaining is a supplementary tissue-level correlate of PRC2 dysfunction.

A normal/retained marker result is not an exclusion criterion.

Slide 66 · Diagnostic synthesis rather than a checklist

Morphology

Spindle-cell malignancy?

Anatomic setting

Nerve / precursor relation?

Clinical history

NF1 and lesion evolution?

Ancillary evidence

PRC2 / CDKN2A/B clues

Integrated conclusion

Most defensible classification

Slide 67 · Case 1: NF1 and a deep nerve-associated lesion

A patient with NF1 has a deep mass arising in the region of a large peripheral nerve. Histology shows an infiltrative, mitotically active spindle-cell sarcoma.

Which clinical, anatomic and histologic findings most strongly support MPNST?

Slide 68 · Case 1: Integrate the evidence

NF1 provides a recognized predisposition to MPNST.

A clearly demonstrated relationship to a large nerve is important.

Infiltration, spindle-cell fascicles and mitoses support a malignant nerve-sheath lesion.

Consider whether a plexiform neurofibroma precursor is present.

Slide 69 · Case 2: Tumor without known NF1

A patient without documented NF1 has a poorly defined spindle-cell malignancy with no sampled residual neurofibroma. Surgical evaluation suggests origin from a proximal peripheral nerve.

Does the absence of NF1 exclude MPNST? What additional evidence is important?

Slide 70 · Case 2: Sporadic origin remains possible

Sporadic MPNST may arise de novo.

Demonstrable nerve continuity can provide a decisive contextual clue.

Assess overall morphology and use appropriate molecular evidence as support.

Do not infer NF1 solely from the tumor’s presence.

Slide 71 · Case 3: Focal skeletal-muscle phenotype

A malignant spindle-cell tumor closely related to a peripheral nerve contains a focal rhabdomyoblastic component.

What terminology describes the heterologous component and this MPNST variant?

Slide 72 · Case 3: Recognize a Triton tumor

Rhabdomyoblastic elements represent divergent differentiation.

MPNST showing this differentiation is designated a Triton tumor.

The designation depends on the recognizable skeletal-muscle phenotype.

Slide 73 · Case 4: An undifferentiated spindle-cell sarcoma

A high-grade spindle-cell lesion is infiltrative but has no demonstrated NF1 association or nerve continuity. Molecular testing is nonspecific.

Why should the diagnosis of MPNST be approached cautiously?

Slide 74 · Case 4: Maintain diagnostic discipline

Poor differentiation can make distinction from undifferentiated sarcoma difficult.

No single histologic feature makes the diagnosis definitive.

Seek additional clinical, anatomic and molecular evidence before assigning lineage.

Slide 75 · Integrated MPNST concept map

Predisposition

NF1 or sporadic

Progression

Genomic and chromatin alterations

Behavior

Nerve-axis / soft-tissue infiltration

Histology

Spindle fascicles; Atypia; Necrosis

Diagnosis

Context + morphology + ancillaries

Slide 76 · Five diagnostic statements to retain

MPNST is often high grade and may arise from plexiform neurofibroma in NF1.

A sporadic de novo MPNST is also possible.

Tumor infiltration and the nerve relationship are central morphologic/anatomic clues.

PRC2 and CDKN2A/B alterations reinforce, but do not replace, diagnosis.

Triton tumor denotes rhabdomyoblastic divergent differentiation.

Slide 77 · Sources and image provenance

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th ed. (2026); Chapter 27, pp. 1125–1127.

Source-derived slides use the MPNST section and adjacent nerve-sheath tumor sections.

Supplementary H3K27me3 interpretation: 2019 systematic review (PMID 31342317) and mechanistic study (PMID 31175328).

All diagrams are original editable PowerPoint schematics; no clinical/histologic specimens are simulated.